Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression

Abstract. Determining whether glioblastoma multiforme (GBM) is progressing despite treatment is challenging due to the pseudoprogression phenomenon seen on conventional MRIs, but relative cerebral blood volume (CBV) has been shown to be helpful. As CBV’s calculation from perfusion-weighted images is not standardized, we investigated whether there were differences between three FDA-cleared software packages in their CBV output values and subsequent performance regarding predicting survival/progression. Forty-five postradiation therapy GBM cases were retrospectively identified as having indeterminate MRI findings of progression versus pseudoprogression. The dynamic susceptibility contrast MR images were processed with different software and three different relative CBV metrics based on the abnormally enhancing regions were computed. The intersoftware intraclass correlation coefficients were 0.8 and below, depending on the metric used. No statistically significant difference in progression determination performance was found between the software packages, but performance was better for the cohort imaged at 3.0 T versus those imaged at 1.5 T for many relative CBV metric and classification criteria combinations. The results revealed clinically significant variation in relative CBV measures based on the software used, but minimal interoperator variation. We recommend against using specific relative CBV measurement thresholds for GBM progression determination unless the same software or processing algorithm is used.

[1]  M Takahashi,et al.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.

[2]  Leland S. Hu,et al.  Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival , 2012, Neuro-oncology.

[3]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[4]  Girolamo Crisi,et al.  Differences in Dynamic Susceptibility Contrast MR Perfusion Maps Generated by Different Methods Implemented in Commercial Software , 2014, Journal of computer assisted tomography.

[5]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[6]  Chul-Kee Park,et al.  Gliomas: Application of Cumulative Histogram Analysis of Normalized Cerebral Blood Volume on 3 T MRI to Tumor Grading , 2013, PloS one.

[7]  Cem Parlak,et al.  Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and Temozolomide , 2012, American journal of clinical oncology.

[8]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[9]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[10]  Daniel P Barboriak,et al.  Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. , 2006, Radiology.

[11]  Steven Piantadosi,et al.  Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States , 2010, Clinical Cancer Research.

[12]  Parinaz Massoumzadeh,et al.  Comparison of perfusion- and diffusion-weighted imaging parameters in brain tumor studies processed using different software platforms. , 2014, Academic radiology.

[13]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[14]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[15]  W. Shi,et al.  Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma , 2011, Neurology.

[16]  P. Box Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .

[17]  K. McGraw,et al.  Forming inferences about some intraclass correlation coefficients. , 1996 .

[18]  J. Le Bas,et al.  Perfusion magnetic resonance imaging: comparison of semiologic characteristics in first-pass perfusion of brain tumors at 1.5 and 3 Tesla. , 2012, Journal of neuroradiology. Journal de neuroradiologie.

[19]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[20]  J. Boxerman,et al.  The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.

[21]  N. Otsu A threshold selection method from gray level histograms , 1979 .

[22]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[23]  Hiroki Shirato,et al.  Accuracy and reliability assessment of CT and MR perfusion analysis software using a digital phantom. , 2013, Radiology.

[24]  Ronald L. Wolf,et al.  Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. , 2009, Radiology.

[25]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[26]  Ramazan Yildiz,et al.  Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide , 2010, Clinical Neurology and Neurosurgery.

[27]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[28]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.